Cathie's Ark Logo
Caredx Inc Logo

ARKG Holdings of CareDx (CDNA) - Updated Daily

GenomicsGenetic Testing
Date
Direction
Shares
Fund Weight
Fund
May 11, 2023
BUY110.667k0.0481%ARKG
February 9, 2023
BUY34.955k0.0243%ARKG
February 8, 2023
BUY140.742k0.0947%ARKG
February 1, 2023
BUY1.923k0.0013%ARKG
January 30, 2023
BUY89.781k0.058%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
2.57%$431.96m
🏋🏿‍♂️Weight Rank In ARKG🌏Country
15🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
38$37.89
🎫ARK Ownership Percent
12.32%
Description
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Website
caredx.com

Other ETFs That Hold CDNA

Ticker
NameWeight
ARKGARK Genomic Revolution ETF3.5%
GNOMGlobal X Genomics & Biotechnology ETF0.92%
XBISPDR® S&P Biotech ETF0.61%
LABUS&P Biotech Bull 3X Shares ETF0.102%
IBBiShares Biotechnology ETF0.06%

Research Notes and Commentary for CDNA

No Research Notes Found for CDNA